Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Sep 2025 value amounting to $22.2 million.

  • Ironwood Pharmaceuticals' Other Non-Current Liabilities fell 44.14% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 44.14%. This contributed to the annual value of $17.1 million for FY2024, which is 39.80% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Other Non-Current Liabilities of $22.2 million as of Q3 2025, which was down 1.10% from $22.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $39.8 million during Q3 2024, with a 5-year trough of $1.5 million in Q2 2021.
  • In the last 3 years, Ironwood Pharmaceuticals' Other Non-Current Liabilities had a median value of $28.4 million in 2023 and averaged $25.9 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 478.86% in 2022, then slumped by 44.14% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $3.5 million in 2021, then soared by 178.95% to $9.8 million in 2022, then spiked by 190.96% to $28.4 million in 2023, then tumbled by 39.80% to $17.1 million in 2024, then tumbled by 44.14% to $22.2 million in 2025.
  • Its Other Non-Current Liabilities was $22.2 million in Q3 2025, compared to $22.5 million in Q2 2025 and $17.3 million in Q1 2025.